Focus: Cognito Therapeutics is a public-stage biotech company headquartered in Cambridge, MA, focused on device-based brain therapies for neurological disorders, specifically Alzheimer's disease. The company is transitioning from development to commercialization with recent funding and executive appointments signaling market-entry preparation.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Cognito Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cognito Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cognito Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Four Alzheimer’s companies to watch at AAIC 2026 - Longevity.Technology
Four Alzheimer’s companies to watch at AAIC 2026 Longevity.Technology
Cognito Therapeutics - 2026 Funding Rounds & List of Investors - Tracxn
Cognito Therapeutics - 2026 Funding Rounds & List of Investors Tracxn
Cognito Therapeutics, Ochsner team up for new brain health approaches - Pharmaceutical Technology
Cognito Therapeutics, Ochsner team up for new brain health approaches Pharmaceutical Technology
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio - Business Wire
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio Business Wire
Cognito raises $105M to bring Alzheimer’s treatment device to market - MedTech Dive
Cognito raises $105M to bring Alzheimer’s treatment device to market MedTech Dive
$105 Million Brings Cognito, And Neurotech, to a Pivotal Stage - Forbes
$105 Million Brings Cognito, And Neurotech, to a Pivotal Stage Forbes
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles